Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208994 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ANLRP3IRAK4 | |
| SCHEMBL18208934 | 0.90 | TNKS (0.55) | SMN1; SMN2IRAK4KDM4EHSD17B10TNKS | |
| SCHEMBL18208937 | 0.90 | TNKS (0.55) | SMN1; SMN2IRAK4KDM4EHSD17B10TNKS | |
| SCHEMBL18208212 | 0.86 | JAK2 (0.52) | SMN1; SMN2IRAK4JAK2KDM4EHSD17B10 | |
| SCHEMBL18208215 | 0.86 | JAK2 (0.52) | SMN1; SMN2IRAK4JAK2KDM4EHSD17B10 | |
| SCHEMBL18208721 | 0.86 | KDM4E (0.52) | SMN1; SMN2IRAK4JAK2KDM4EHSD17B10 | |
| SCHEMBL18208718 | 0.86 | KDM4E (0.52) | SMN1; SMN2IRAK4JAK2KDM4EHSD17B10 | |
| SCHEMBL18208419 | 0.86 | KDM4E (0.52) | SMN1; SMN2NPC1RAB9AIRAK4JAK2 | |
| SCHEMBL18208420 | 0.86 | KDM4E (0.52) | SMN1; SMN2NPC1RAB9AIRAK4JAK2 | |
| SCHEMBL18208122 | 0.85 | KDM4E (0.50) | SMN1; SMN2IRAK4JAK2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | claimed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | SMN1; SMN2 1153/4885NPC1 558/4885RAB9A 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.